Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Alector, Inc. before investing.

In this article, we go over a few key elements for understanding Alector, Inc.’s stock price such as:

• Alector, Inc.’s current stock price and volume
• Why Alector, Inc.’s stock price changed recently
• Upgrades and downgrades for ALEC from analysts
• ALEC’s stock price momentum as measured by its relative strength

About Alector, Inc. (ALEC)

Before we jump into Alector, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company’s products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. In addition, the company’s preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson’s disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Want to learn more about Alector, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Alector, Inc..

Alector, Inc.’s Stock Price as of Market Close

As of May 02, 2025, 12:45 PM, CST, Alector, Inc.’s stock price was $1.300.

Alector, Inc. is up 6.56% from its previous closing price of $1.220.

During the last market session, Alector, Inc.’s stock traded between $1.220 and $1.320. Currently, there are approximately 98.32 million shares outstanding for Alector, Inc..

Alector, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Alector, Inc. Stock Price History

Alector, Inc.’s (ALEC) price is currently up 8.33% so far this month.

During the month of May, Alector, Inc.’s stock price has reached a high of $1.320 and a low of $1.110.

Over the last year, Alector, Inc. has hit prices as high as $6.780 and as low as $0.870. Year to date, Alector, Inc.’s stock is down 31.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Alector, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of May 01, 2025,, no analysts have changed their rating of Alector, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Alector, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Alector, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Alector, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Alector, Inc. (ALEC) by visiting AAII Stock Evaluator.

Relative Price Strength of Alector, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 01, 2025, Alector, Inc. has a weighted four-quarter relative price strength of -24.50%, which translates to a Momentum Score of 9 and is considered to be Very Weak.

Want to learn more about how Alector, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Alector, Inc. Stock Price: Bottom Line

As of May 2, 2025, Alector, Inc.’s stock price is $1.300, which is up 6.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Alector, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.